== Prognose ==
Relativ 5-årig overlevelsesrate: i alderen 20-44,76%. 45-54 år: 67%. Alder 55-64 år: 45%.<ref>{{cite web |title=Survival Rates for Selected Adult Brain and Spinal Cord Tumors |url=https://www.cancer.org/cancer/brain-spinal-cord-tumors-adults/detection-diagnosis-staging/survival-rates.html#references |website=American Cancer Society |access-date=8. januar 2021}}</ref><ref>{{Cite journal |last1=Ostrom |first1=Quinn T. |last2=Gittleman |first2=Haley |last3=Liao |first3=Peter |last4=Vecchione-Koval |first4=Toni |last5=Wolinsky |first5=Yingli |last6=Kruchko |first6=Carol |last7=Barnholtz-Sloan |first7=Jill S. |date=oktober 2017 |title=CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014 |journal=Neuro-Oncology |volume=19 |issue=S5 |pages=v1–v88 |doi=10.1093/neuonc/nox158 |pmid=29117289 |doi-access=free}}</ref> Procarbazin, lomustin og vincristin er blevet anvendt siden maj 1975. I 48 år har terapistudier regelmæssigt testet nye behandlingsmuligheder for at forbedre behandlingen af anaplastisk oligodendrogliom.<ref name="pmid1122488"<ref>{{cite journal | vauthors = Gutin PH, Wilson CB, Kumar AR, Boldrey EB, Levin V, Powell M, Enot KJ | title = Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors | url = https://archive.org/details/sim_cancer_1975-05_35_5/page/1398 | journal = Cancer | volume = 35 | issue = 5 | pages = 1398–404 | date = maj 1975 | pmid = 1122488 | doi = 10.1002/1097-0142(197505)35:5<1398::aid-cncr2820350524>3.0.co;2-c | doi-access = free }}</ref>
Sygdomme